Joshua Schafer Sells 10,500 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) insider Joshua Schafer sold 10,500 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $9.19, for a total value of $96,495.00. Following the sale, the insider owned 62,278 shares in the company, valued at approximately $572,334.82. The trade was a 14.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Joshua Schafer also recently made the following trade(s):

• On Friday, January 30th, Joshua Schafer sold 3,375 shares of Zevra Therapeutics stock. The stock was sold at an average price of $8.83, for a total transaction of $29,801.25.

Zevra Therapeutics Stock Down 6.5%

ZVRA stock opened at $8.36 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 8.62 and a quick ratio of 8.57. The firm has a market capitalization of $470.65 million, a P/E ratio of 17.79 and a beta of 0.99. Zevra Therapeutics, Inc. has a 52-week low of $6.19 and a 52-week high of $13.16. The company’s 50 day simple moving average is $8.67 and its 200-day simple moving average is $9.40.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.03. The firm had revenue of $26.06 million for the quarter, compared to analysts’ expectations of $26.64 million. Zevra Therapeutics had a net margin of 41.93% and a negative return on equity of 51.40%. As a group, equities research analysts anticipate that Zevra Therapeutics, Inc. will post -1.95 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ZVRA. HC Wainwright set a $26.00 price objective on Zevra Therapeutics in a research note on Tuesday, December 30th. Wall Street Zen upgraded shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Zevra Therapeutics in a research report on Friday, January 9th. Cantor Fitzgerald cut their target price on shares of Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. Finally, Canaccord Genuity Group decreased their target price on shares of Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research note on Thursday, November 6th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $22.80.

Hedge Funds Weigh In On Zevra Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ZVRA. Bailard Inc. acquired a new stake in Zevra Therapeutics in the fourth quarter valued at approximately $116,000. UBS Group AG raised its holdings in shares of Zevra Therapeutics by 30.9% during the 4th quarter. UBS Group AG now owns 285,488 shares of the company’s stock valued at $2,558,000 after purchasing an additional 67,392 shares in the last quarter. Sanctuary Advisors LLC raised its holdings in shares of Zevra Therapeutics by 18.0% during the 4th quarter. Sanctuary Advisors LLC now owns 34,461 shares of the company’s stock valued at $309,000 after purchasing an additional 5,247 shares in the last quarter. Retirement Planning Co of New England Inc. lifted its stake in shares of Zevra Therapeutics by 10.4% in the 4th quarter. Retirement Planning Co of New England Inc. now owns 662,976 shares of the company’s stock valued at $5,940,000 after purchasing an additional 62,206 shares during the last quarter. Finally, Stratos Wealth Partners LTD. boosted its holdings in Zevra Therapeutics by 78.6% in the fourth quarter. Stratos Wealth Partners LTD. now owns 409,000 shares of the company’s stock worth $3,665,000 after purchasing an additional 180,000 shares in the last quarter. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.